ORPHA:397
Giant cell arteritis
Also known as: Horton disease · Temporal arteritis
Publications
19,144
98.5th percentile
Trials
61
Interventional, condition-specific
Researchers
1,155
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare large vessel vasculitis (LVV) characterized by vasculitis predominantly involving the arteries originating from the aortic arch and the extracranial branches of the carotid arteries. Clinical manifestations are variable, the predominant cranial is characterized by headache, jaw claudication, scalp tenderness and visual symptoms and the predominant LVV type by constitutional symptoms, polymyalgia rheumatica and occasionally limb ischemia. Overlaps between these two phenotypes are common.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008538
- OMIM:187360
- UMLS:C1956391
- NCIT:C35065
Additional Mondo synonyms (5)
Giant Cell Arteritis · giant cell arteritis · inflammation of temporal artery · temporal arteritis · temporal artery inflammation
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
19,144 matched papers (9,351 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
61 matched on ClinicalTrials.gov (14 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
19,144
19,144 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
19,144 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
9,351 in the last 10 years · high confidence · 98.5th percentile (publications denominator)
Phrase hits: 19,144 · MeSH hits: 0
Who's working on it?
1,155
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Dejaco C6 papers · 2026
Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy; Department of Rheumatology, Medical University of Graz, Graz, Austria.
Papers in Europe PMC - 02Makhzoum JP6 papers · 2026
Division of Internal Medicine, Vasculitis Clinic, Hopital Sacré-Coeur de Montréal, University of Montréal, Montréal, Quebec, Canada.
Papers in Europe PMC - 03Castañeda S5 papers · 2026
Hospital de la Princesa, IIS-Princesa, Department of Rheumatology, Madrid, Spain.
Papers in Europe PMC - 04Salvarani C5 papers · 2026
Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; Università di Modena e Reggio Emilia, Reggio Emilia, Italy.
Papers in Europe PMC - 05Samson M5 papers · 2026
Department of Internal Medicine and Clinical Immunology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Dijon-Bourgogne University Hospital, University EPE Bourgogne Europe, Dijon, France.
Papers in Europe PMC - 06Schmidt WA5 papers · 2026
Department of Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany; Waldfriede Hospital, Rheumatology, Berlin, Germany.
Papers in Europe PMC - 07Bley TA4 papers · 2026
Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, Germany.
Papers in Europe PMC - 08Cid MC4 papers · 2026
Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Papers in Europe PMC - 09Espitia O4 papers · 2026
Department of Internal and Vascular Medicine, Nantes Université, CHU Nantes, Nantes, France Olivier.espitia@chu-nantes.fr.
Papers in Europe PMC - 10Guggenberger KV4 papers · 2026
Department of Diagnostic and Interventional Neuroradiology, University Hospital Würzburg, Würzburg, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
61
interventional trials for this specific condition
61 interventional trials matched this specific condition name; 14 currently recruiting in our sample. 36 trials are registered for arteritis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
61 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.5th percentile).
high confidence · 97.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
61 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06957002·NOT YET RECRUITING·Bosentan in the Treatment of Giant Cell Arteritis
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT07060274·RECRUITING·Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients
Conditions: Giant Cell Arteritis (GCA) · Doppler Ultrasound·Matched via name phrase
- NCT06335888·RECRUITING·A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT07001059·RECRUITING·oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT04012905·RECRUITING·Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT06833411·NOT YET RECRUITING·Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT07720804·NOT YET RECRUITING·Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study (GIDEON)
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT06763783·ENROLLING BY INVITATION·Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
Conditions: Systemic Vasculitis · Spondylarthropathies · Psoriatic Arthritis · Scleroderma·Matched via name phrase
- NCT07628075·NOT YET RECRUITING·Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Conditions: Large Vessel Vasculitis · Takayasu Arteritis · Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT06887062·RECRUITING·Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Conditions: Large Vessel Vasculitis · Giant Cell Arteritis (GCA) · Takayasu Arteritis·Matched via name phrase
- NCT05193396·RECRUITING·Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Conditions: Adrenal Insufficiency · Polymyalgia Rheumatica (PMR) · Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT07108387·RECRUITING·Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT05435781·RECRUITING·Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
Conditions: Adrenal Insufficiency · Polymyalgia Rheumatica · Giant Cell Arteritis·Matched via name phrase
- NCT04474847·RECRUITING·Abatacept for the Treatment of Giant Cell Arteritis
Conditions: Giant Cell Arteritis·Matched via name phrase
Broader category: arteritis
36
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07325357·NOT YET RECRUITING·Effect of Pirfenidone on TA Fibrosis
Conditions: Takayasu Arteritis·Matched via name phrase
- NCT06498089·RECRUITING·A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
Conditions: Takayasu Arteritis·Matched via name phrase
- NCT06178419·RECRUITING·Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)
Conditions: Cerebral Ischemia · Takayasu Arteritis·Matched via name phrase
- NCT07013838·NOT YET RECRUITING·The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
Conditions: Takayasu Arteritis (TAK)·Matched via name phrase
- NCT05102448·RECRUITING·Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
Conditions: Takayasu Arteritis·Matched via name phrase
- NCT07451665·NOT YET RECRUITING·Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
Conditions: Takayasu Arteritis (TAK)·Matched via name phrase
- NCT07087912·RECRUITING·Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Conditions: Rheumatoid Arthritis (RA) · Juvenile Idiopathic Arthritis (JIA) · Systemic Lupus Erythematosus (SLE) · Juvenile Systemic Lupus Erythematosus·Matched via name phrase
- NCT04300686·RECRUITING·A Pilot Study in Severe Patients With Takayasu Arteritis.
Conditions: Takayasu Arteritis · Tocilizumab · Adalimumab · Treatment·Matched via name phrase
- NCT07477795·NOT YET RECRUITING·Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Conditions: Takayasu Arteritis · Large Vessel Vasculitis·Matched via name phrase
- NCT07491913·RECRUITING·Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Conditions: Takayasu Arteritis·Matched via name phrase
Observational and natural-history studies
75 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06271018·RECRUITING·TocILizumab in aorTitis in GCA (TILT)
Conditions: Aortitis · Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT05935709·RECRUITING·DANIsh VASculitis Database (DANIVAS)
Conditions: Giant Cell Arteritis · Polymyalgia Rheumatica·Matched via name phrase
- NCT05904301·RECRUITING·Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Conditions: Behcet Disease · Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis · Takayasu Arteritis · Giant Cell Arteritis·Matched via name phrase
- NCT07246577·RECRUITING·The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT06609668·RECRUITING·Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)
Conditions: Giant Cell Arteritis (GCA) · Polymyalgia Rheumatica (PMR)·Matched via name phrase
- NCT06894602·RECRUITING·Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT07150000·RECRUITING·Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
Conditions: Rheumatic Diseases · Rheumatoid Arthritis (RA) · Giant Cell Arteritis (GCA) · Psoriatic Arthritis (PsA)·Matched via name phrase
- NCT04102930·RECRUITING·Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
Conditions: Giant Cell Arteritis · Polymyalgia Rheumatica·Matched via name phrase
- NCT07206238·RECRUITING·Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis
Conditions: Giant Cell Arteritis (GCA) · Ischemic Optic Neuropathy · NAION - Non-Arteritic Ischemic Optic Neuropathy·Matched via name phrase
- NCT06004154·RECRUITING·Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT06500728·RECRUITING·Visual Involvement in Giant Cell Arteritis
Conditions: Giant Cell Arteritis · Visual Impairment · Central Retinal Artery Occlusion · Anterior Ischemic Optic Neuropathy·Matched via name phrase
- NCT06696027·RECRUITING·AYLo - AutoimmunitY and Loss of y
Conditions: Giant Cell Arteritis (GCA) · Polymyalgia Rheumatica (PMR) · ANCA Associated Vasculitis (AAV) · Idiopathic Inflammatory Myopathies·Matched via name phrase
- NCT02967068·RECRUITING·VCRC Tissue Repository
Conditions: Aortitis · Cutaneous Vasculitis · Eosinophilic Granulomatosis With Polyangiitis · Giant Cell Arteritis·Matched via name phrase
- NCT07354906·NOT YET RECRUITING·Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT06742671·RECRUITING·Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Giant cell arteritis" OR "Horton disease" OR "Temporal arteritis" OR "inflammation of temporal artery" OR "inflammation of the temporal artery" OR "temporal artery inflammation"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Giant cell arteritis" OR "Horton disease" OR "Temporal arteritis" OR "inflammation of temporal artery" OR "inflammation of the temporal artery" OR "temporal artery inflammation"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 61 interventional · 75 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"arteritis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T13:42:51.558Z
